- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Doug Hillblom on the State of e-Prescribing and Remaining Barriers
Rates of e-prescribing access is higher among pharmacists than physicians, which is partly due to older physicians at the end of their career who find implementing the system cost prohibitive, explained Doug Hillblom, PharmD, president at Arena Healthcare, LLC.
Rates of e-prescribing access is higher among pharmacists than physicians, which is partly due to older physicians at the end of their career who find implementing the system cost prohibitive, explained Doug Hillblom, PharmD, President at Arena Healthcare, LLC.
Transcript
What is the current state of e-prescribing in the United States?
E-prescribing in general, approximately 75% of physician practices, 95% of pharmacies are actively engaged for e-prescribing transactions. What we see is that in the physicians it is a little lower and some of it has to do with age of physicians or the size of the practice. But in pharmacies, basically about 95%, very, very few are not accepting those today and even that number will be increasing in the future.
What barriers are preventing further adoption of e-prescribing?
From the physician point of view is cost. Putting in an electronic health record is, for many smaller groups or older physicians who are looking at the end of their career, it’s somewhat cost prohibitive. The new technology and getting used to it and understanding that, they tend to have a little more resistance to it.
From the pharmacy end, there are certain types of practices that feel that e-prescribing doesn’t have any business linked to them. I think about those and go, “hmm.” I know 1 from personal experience that didn’t do electronic prescriptions because there was 1 doctor in town and 1 pharmacy and they were in the same building. So they just didn’t see a business need to do it. But, you know, that’s the unique situation, not the norm.
Physician-wise, I have a lot of friends who are doing e-prescribing and find it to be quite helpful. There are components of e-prescribing that we don’t even talk about. We think about just the initiation of prescription. Things like refills, getting refills into their electronic health records and being able to authorize those is really actually also part of the e-prescribing system or environment.
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Study Validates Smartphone Analysis for Predicting Obstructive Sleep Apnea
November 29th 2023Findings show breathing sounds recorded by smartphones during sleep at home can reliably identify obstructive sleep apnea, presenting an innovative and accessible alternative to traditional in-laboratory polysomnography.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Researchers Identify Potential Biomarkers for SMA Motor Improvement Following Nusinersen Treatment
November 17th 2023A retrospective, exploratory analysis identifies biomarkers predictive of spinal muscular atrophy (SMA) response to nusinersen and suggests the efficacy of using machine learning algorithms to anticipate patient outcomes.
Read More
Data on Delandistrogene Moxeparvovec Can Inform Future Gene Therapies
November 17th 2023The FDA approved delandistrogene moxeparvovec-rokl (Elevidys, Sarepta Therapeutics) in June to treat Duchenne muscular dystrophy in ambulatory pediatric patients aged 4 through 5 who have a confirmed DMD gene mutation.
Read More
